|

LBL-024 for Injection Clinical Trials

7 actively recruiting trials

No change since May 2026

Also known as: LBL-024

Pipeline

Phase 2: 4Phase 1/2: 3

Top Sponsors

  • Nanjing Leads Biolabs Co.,Ltd7

Indications

  • Cancer7
  • Advanced Solid Tumour4
  • Triple Negative Breast Cancer1
  • Advanced Solid Tumor1
  • Ovarian Cancer1

Other7 trials

A Clinical Trial of LBL-024 Combination Drug in Patients With Advanced Solid Tumours[Substudy 01(NSCLC)]
Phase 2
A Clinical Trial of LBL-024 Combination Drug in Patients With Advanced Solid Tumours[Substudy 02(BTC&HCC)]
Phase 2
A Phase I/II Clinical Study of LBL-024 in Patients With Advanced Malignant Tumors
Phase 1/2
A Phase II Clinical Study of LBL-024 Combination Therapy in Patients With Advanced Solid Tumour[Substudy 03(ESCC)]
Phase 2
A Phase II Clinical Trial of LBL-024 Combination Drug in Patients With Advanced Solid Tumour[Substudy 04]
Phase 2
A Phase Ib/Ⅱ Clinical Trial of LBL-024 Combined With Paclitaxel in Patients With Platinum-resistant Ovarian Cancer
Phase 1/2
A Trial of LBL-024 Monotherapy or Combination Drug in Patients With Triple Negative Breast Cancer
Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.